Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio

Core Insights - Biogen has entered into a license agreement with Vanqua Bio for exclusive worldwide rights to a preclinical oral C5aR1 antagonist, aimed at addressing various inflammatory disorders with high unmet needs [1][2][3] Company Overview - Biogen is a leading biotechnology company founded in 1978, focused on innovative science to develop new medicines and create value for shareholders and communities [4] - Vanqua Bio, established in 2019, specializes in discovering and developing next-generation medicines for neurodegenerative and inflammatory diseases [6] Agreement Details - The agreement includes a $70 million upfront payment to Vanqua Bio and potential additional payments up to $990 million based on development, regulatory, commercial, and sales milestones, along with tiered royalties on net sales [3] - Biogen plans to record the upfront payment as an Acquired In-Process Research and Development expense in Q4 2025 [3] Strategic Focus - The C5aR1 antagonist is expected to enhance Biogen's immunology pipeline by providing an oral mechanism applicable across multiple immune-mediated diseases [2] - The C5aR1 target is validated for its role in neutrophil-mediated inflammation, which is significant in various inflammatory disorders [2]